Literature DB >> 15596412

Elevated monocyte chemotactic proteins 1, 2, and 3 in pulmonary alveolar proteinosis are associated with chemokine receptor suppression.

Tracey L Bonfield1, Nejimol John, Anagha Malur, Barbara P Barna, Daniel A Culver, Mani S Kavuru, Mary Jane Thomassen.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare autoimmune lung disease characterized by abnormal surfactant accumulation within alveolar macrophages, and circulating auto-antibodies against granulocyte-macrophage colony stimulating factor (GM-CSF) resulting in functional GM-CSF deficiency. Monocyte/macrophage chemotactic protein-1 (MCP-1) is elevated in PAP, suggesting association with the pathophysiology. Because PAP has been associated with inflammatory pulmonary changes, we hypothesized that other MCP family chemokines would be present and that Chemokine Chemotaxis Receptor 2 (CCR2) would be elevated on PAP mononuclear cells. Here we show for the first time that MCP-2 and MCP-3, like MCP-1, are highly elevated in PAP. We also confirm that PAP alveolar macrophages and not epithelial cells produce MCP-1, and that MCP-1 from PAP lung has functional chemoattractant activity. Surprisingly, CCR2 expression is diminished in PAP lymphocytes and alveolar macrophages compared to controls. Further, MCP-1 from PAP lung suppresses CCR2 expression in vitro, suggesting that in PAP, MCP-1 participates in an autocrine regulatory network in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15596412     DOI: 10.1016/j.clim.2004.09.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  6 in total

1.  Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy.

Authors:  Takuji Suzuki; Takuro Sakagami; Lisa R Young; Brenna C Carey; Robert E Wood; Maurizio Luisetti; Susan E Wert; Bruce K Rubin; Katharine Kevill; Claudia Chalk; Jeffrey A Whitsett; Carrie Stevens; Lawrence M Nogee; Ilaria Campo; Bruce C Trapnell
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

2.  Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis.

Authors:  Morgan T Sutton; David Fletcher; Nicole Episalla; Lauren Auster; Sukhmani Kaur; Mary Chandler Gwin; Michael Folz; Dante Velasquez; Varun Roy; Rolf van Heeckeren; Donald P Lennon; Arnold I Caplan; Tracey L Bonfield
Journal:  J Stem Cell Res Ther       Date:  2017-09-22

3.  A role for MCP-1/CCR2 in interstitial lung disease in children.

Authors:  Dominik Hartl; Matthias Griese; Thomas Nicolai; Gernot Zissel; Christine Prell; Dietrich Reinhardt; Dolores J Schendel; Susanne Krauss-Etschmann
Journal:  Respir Res       Date:  2005-08-11

4.  Alveolar macrophages of GM-CSF knockout mice exhibit mixed M1 and M2 phenotypes.

Authors:  Heidi Dalrymple; Barbara P Barna; Anagha Malur; Achut G Malur; Mani S Kavuru; Mary Jane Thomassen
Journal:  BMC Immunol       Date:  2013-09-17       Impact factor: 3.615

5.  Evidence for chemokine synergy during neutrophil migration in ARDS.

Authors:  Andrew E Williams; Ricardo J José; Paul F Mercer; David Brealey; Dhruv Parekh; David R Thickett; Cecelia O'Kane; Danny F McAuley; Rachel C Chambers
Journal:  Thorax       Date:  2016-08-05       Impact factor: 9.139

6.  A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity.

Authors:  Feng-Ying Huang; Jin-Yan Wang; Shu-Zhen Dai; Ying-Ying Lin; Yan Sun; Liming Zhang; Zhuoxuan Lu; Rong Cao; Guang-Hong Tan
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.